Advertisement
Screener

Ernexa Therapeutics Inc. (ERNA) Share-based Payment Arrangement, Expense

2.8 / 5 stars · 68/120 Roast Me

Ernexa Therapeutics Inc. Share-based Payment Arrangement, Expense

Ernexa Therapeutics Inc. (ERNA) reported Share-based Payment Arrangement, Expense of $320.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-06

  • Ernexa Therapeutics Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $320.00K, a 13.04% decline year-over-year.
  • Ernexa Therapeutics Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $308.00K, a 38.65% decline year-over-year.
  • Ernexa Therapeutics Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $333.00K, a 18.78% decline year-over-year.
  • Ernexa Therapeutics Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $293.00K, a 27.65% decline year-over-year.
  • Ernexa Therapeutics Inc. share-based payment arrangement, expense for fiscal 2025 was $1.50M, a 1.58% decline from fiscal 2024.
  • Ernexa Therapeutics Inc. share-based payment arrangement, expense for fiscal 2024 was $1.52M, a 22.38% increase from fiscal 2023.
  • Ernexa Therapeutics Inc. share-based payment arrangement, expense for fiscal 2023 was $1.24M, a 57.68% decline from fiscal 2022.
  • Ernexa Therapeutics Inc. share-based payment arrangement, expense for fiscal 2022 was $2.94M, a 43.94% decline from fiscal 2021.
Period endShare-based Payment Arrangement, Expense 3 monthShare-based Payment Arrangement, Expense 3 month as first filedShare-based Payment Arrangement, Expense 6 monthShare-based Payment Arrangement, Expense 6 month as first filedShare-based Payment Arrangement, Expense 9 monthShare-based Payment Arrangement, Expense 9 month as first filedShare-based Payment Arrangement, Expense 12 month
2026-06-30$320.00K
10-Q · filed 2026-08-06
$629.00K
10-Q · filed 2026-08-06
$961.00K
derived: sum of 3 quarters · filed 2026-08-06
$1.25M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$308.00K
10-Q · filed 2026-05-11
$641.00K
derived: sum of 2 quarters · filed 2026-05-11
$934.00K
derived: sum of 3 quarters · filed 2026-05-11
$1.30M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$333.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13
$626.00K
derived: sum of 2 quarters · filed 2026-03-13
$994.00K
derived: sum of 3 quarters · filed 2026-08-06
$1.50M
10-K · filed 2026-03-13
2025-09-30$293.00K
10-Q · filed 2025-11-07
$661.00K
derived: sum of 2 quarters · filed 2026-08-06
$1.16M
10-Q · filed 2025-11-07
$1.57M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$368.00K
10-Q · filed 2026-08-06
$870.00K
10-Q · filed 2026-08-06
$1.28M
derived: sum of 3 quarters · filed 2026-08-06
$1.69M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$502.00K
10-Q · filed 2026-05-11
$912.00K
derived: sum of 2 quarters · filed 2026-05-11
$1.32M
derived: sum of 3 quarters · filed 2026-05-11
$1.74M
derived: sum of 4 quarters · filed 2026-05-11
2024-12-31$410.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13
$815.00K
derived: sum of 2 quarters · filed 2026-03-13
$1.24M
derived: sum of 3 quarters · filed 2026-03-13
$1.52M
10-K · filed 2026-03-13
2024-09-30$405.00K
10-Q · filed 2025-11-07
$828.00K
derived: sum of 2 quarters · filed 2025-11-07
$1.11M
10-Q · filed 2025-11-07
$1.27M
derived: sum of 4 quarters · filed 2025-11-07
2024-06-30$423.00K
10-Q · filed 2025-08-13
$705.00K
10-Q · filed 2025-08-13
$870.00K
derived: sum of 3 quarters · filed 2025-08-13
$1.04M
derived: sum of 4 quarters · filed 2025-08-13
2024-03-31$282.00K
10-Q · filed 2025-05-07
$447.00K
derived: sum of 2 quarters · filed 2025-05-07
$621.00K
derived: sum of 3 quarters · filed 2025-05-07
$835.00K
derived: sum of 4 quarters · filed 2025-05-07
2023-12-31$165.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12
$339.00K
derived: sum of 2 quarters · filed 2025-03-12
$553.00K
derived: sum of 3 quarters · filed 2025-03-12
$1.24M
10-K · filed 2025-03-12
2023-09-30$174.00K
10-Q · filed 2024-11-12
$388.00K
derived: sum of 2 quarters · filed 2024-11-12
$1.08M
10-Q · filed 2024-11-12
$1.47M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30$214.00K
10-Q · filed 2024-08-13
$903.00K
10-Q · filed 2024-08-13
$1.30M
derived: sum of 3 quarters · filed 2024-08-13
$1.78M
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31$689.00K
10-Q · filed 2024-05-14
$1.09M
derived: sum of 2 quarters · filed 2024-05-14
$1.56M
derived: sum of 3 quarters · filed 2024-05-14
$2.44M
derived: sum of 4 quarters · filed 2024-05-14
2022-12-31$397.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14
$873.00K
derived: sum of 2 quarters · filed 2024-03-14
$1.75M
derived: sum of 3 quarters · filed 2024-03-14
$2.94M
10-K · filed 2024-03-14
2022-09-30$476.00K
10-Q · filed 2023-11-13
$1.35M
derived: sum of 2 quarters · filed 2023-11-13
$2.54M
10-Q · filed 2023-11-13
$4.47M
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30$879.00K
10-Q · filed 2023-08-11
$2.06M
10-Q · filed 2023-08-11
$4.00M
derived: sum of 3 quarters · filed 2023-08-11
$5.72M
derived: sum of 4 quarters · filed 2023-08-11
2022-03-31$1.18M
10-Q · filed 2023-05-11
$3.12M
derived: sum of 2 quarters · filed 2023-05-11
$4.84M
derived: sum of 3 quarters · filed 2023-05-11
$6.00M
derived: sum of 4 quarters · filed 2023-05-11
2021-12-31$1.93M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20
$3.66M
derived: sum of 2 quarters · filed 2023-03-20
$4.82M
derived: sum of 3 quarters · filed 2023-03-20
$5.24M
10-K · filed 2023-03-20
2021-09-30$1.73M
10-Q · filed 2022-11-14
$1.73M
10-Q · filed 2021-11-12
$2.88M
derived: sum of 2 quarters · filed 2022-11-14
$3.30M
10-Q · filed 2022-11-14
$3.30M
10-Q · filed 2021-11-12
$3.07M
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30$1.15M
10-Q · filed 2022-08-11
$1.15M
10-Q · filed 2021-08-13
$1.57M
10-Q · filed 2022-08-11
$1.57M
10-Q · filed 2021-08-13
$1.35M
derived: sum of 3 quarters · filed 2022-08-11
$1.37M
derived: sum of 4 quarters · filed 2022-08-11
2021-03-31$169.00K
10-Q · filed 2021-05-17
$191.79K
derived: sum of 2 quarters · filed 2022-07-01
$214.53K
derived: sum of 3 quarters · filed 2022-07-01
$237.26K
derived: sum of 4 quarters · filed 2022-07-01
2020-12-31$22.80K
derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-07-01
$45.53K
derived: sum of 2 quarters · filed 2022-07-01
$68.27K
derived: sum of 3 quarters · filed 2022-07-01
$91.00K
10-K/A · filed 2022-07-01
2020-09-30$22.73K
10-Q · filed 2021-11-12
$45.47K
derived: sum of 2 quarters · filed 2021-11-12
$68.20K
10-Q · filed 2021-11-12
2020-06-30$22.73K
10-Q · filed 2021-08-13
$45.47K
10-Q · filed 2021-08-13
2020-03-31$22.73K
10-Q · filed 2021-05-17
2015-03-31$99.00K
10-Q · filed 2015-05-08
2014-03-31$52.00K
10-Q · filed 2015-05-08
2013-12-31$132.00K
10-K · filed 2014-03-31
2012-12-31$185.00K
10-K · filed 2014-03-31

Similar stocks

Stock NameCountryMarket CapPE Ratio
Pulmatrix, Inc. (PULM)United States$0.006B
ProPhase Labs, Inc. (PRPH)United States$0.006B-0.06
Xenetic Biosciences, Inc. (XBIO)United States$0.006B
Enveric Biosciences, Inc. (ENVB)United States$0.007B-0.63
Bolt Biotherapeutics, Inc. (BOLT)United States$0.007B-0.26
SYNLOGIC, INC. (SYBX)United States$0.007B
Acurx Pharmaceuticals, Inc. (ACXP)United States$0.007B-0.97
Processa Pharmaceuticals, Inc. (PCSA)United States$0.005B
AMARIN CORP PLC\UK (AMRN)$0.005B-247.24
CNS Pharmaceuticals, Inc. (CNSP)United States$0.007B